Investor FAQs

Show all

General

Please submit your question using our Investor Contact form.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug of which 2 million oral courses have been delivered to the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox on July 13, 2018.
The Company's common stock trades under the stock symbol SIGA.
SIGA's administrative offices are located at 31 East 62nd Street, New York, NY 10065. Additional facilities are located in Corvallis, Oregon.
Shares of the Company's common stock can be bought or sold like any other publicly traded stock.
The Company does not offer a direct share purchase plan.
The Company does not currently issue dividends or have a DRIP program.
American Stock Transfer & Trust Company, which may be reached at 718-921-8293.
The documents that SIGA files with the SEC can be reviewed or downloaded at no charge from our website (see "Financial Information" in the Investor Relations section of http://www.siga.com). The documents can also be obtained at no charge from the SEC website, www.sec.gov.
Any investor questions can be directed to the following individual at Lazar Partners:

David Carey
Tel: 212-867-1768
dcarey@lazarpartners.com    
December 31st